Elka Stefanova

Elka Stefanova

Auto-generated profile, based on publicly available information

Elka Stefanova

Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2020 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
KFK. S. Frederiksen
K. S. Frederiksen
CCC. Cooper
C. Cooper
GFGiovanni B. Frisoni
Giovanni B. Frisoni
LFL. Frölich
L. Frölich
JGJ. Georges
J. Georges
GWG. Waldemar
G. Waldemar
Background and purpose: Dementia is one of the most common disorders and is associated with increased morbidity, mortality and decreased quality of life. The present guideline addresses important medical management issues including systematic medical follow‐up, vascular risk factors in dementia, pain in dementia, use of antipsychotics in dementia and epilepsy in dementia.Methods: A systematic review of the literature was carried out. Based on the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework, we developed a guideline. Where recommendations based on GRADE were not possible, a good practice statement was formulated.Results: Systematic management of vascular risk factors should be performed in patients with mild to moderate dementia as prevention of cerebrovascular pathology may impact on the progression of dementia (Good Practice statement). Individuals with dementia (without previous stroke) and atrial fibrillation should be treated with anticoagulants (weak recommendation). Discontinuation of opioids should be considered in certain individuals with dementia (e.g. for whom there are no signs or symptoms of pain or no clear indication, or suspicion of side effects; Good Practice statement). Behavioral symptoms in persons with dementia should not be treated with mild analgesics (weak recommendation). In all patients with dementia treated with opioids, assessment of the individual risk–benefit ratio should be performed at regular intervals. Regular, preplanned medical follow‐up should be offered to all patients with dementia. The setting will depend on the organization of local health services and should, as a minimum, include general practitioners with easy access to dementia specialists (Good Practice statement). Individuals with dementia and agitation and/or aggression should be treated with atypical antipsychotics only after all non‐pharmacological measures have been proven to be without benefit or in the case of severe self‐harm or harm to others (weak recommendation). Antipsychotics should be discontinued after cessation of behavioral disturbances and in patients in whom there are side effects (Good Practice statement). For treatment of epilepsy in individuals with dementia, newer anticonvulsants should be considered as first‐line therapy (Good Practice statement).Conclusion: This GRADE‐based guideline offers recommendations on several important medical issues in patients with dementia, and thus adds important guidance for clinicians. For some issues, very little or no evidence was identified, highlighting the importance of further studies within these areas.

1 June 2020 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
ESElka Stefanova
Elka Stefanova
ODOlga Dubljević
Olga Dubljević
CHCornelia Herbert
Cornelia Herbert
BFBeth Fairfield
Beth Fairfield
MSMatthias L. Schroeter
Matthias L. Schroeter
LLLeroy Lowe
Leroy Lowe

27 June 2009 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
LŽLjubomir Žiropađa
Ljubomir Žiropađa
ESElka Stefanova
Elka Stefanova
APAleksandra Potrebić
Aleksandra Potrebić
VKVladimir S. Kostić
Vladimir S. Kostić

1 August 2019 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
SMShima Mehrabian
Shima Mehrabian
LSLarissa Schwarzkopf
Larissa Schwarzkopf
SAStefanie Auer
Stefanie Auer
Iva HolmerovaIva Holmerova
Iva Holmerova
MKMilica G Kramberger
Milica G Kramberger
AKAlexander Kurz
Alexander Kurz
Background: Dementia is a particularly severe societal challenge in several countries of the Danube Region due to higher-than-average increment in population longevity, disproportionate increase of the old-age dependency ratio, and selective outward migration of health care professionals. A survey was conducted among dementia experts to obtain a deeper understanding of the dementia care structures and services in this geographical area, and to identify the educational needs of health care professionals, and the availability of assistive technology. Subjects and methods: A standardized questionnaire was sent out to 15 leading dementia experts/clinicians in 10 Danube Region countries inquiring about professional groups involved in dementia care, availability and reimbursement of services, inclusion of dementia in professional education and training, acceptability of Internet-based education, and availability of assistive technology. The authors are the survey respondents. Results: The majority of individuals with dementia receive care in the community rather than in institutions. The roles of medical specialties are disparate. General practitioners usually identify dementia symptoms while specialists contribute most to clinical diagnosis and treatment. Health care professionals, particularly those who work closely with patients and carers, have limited access to dementia-specific education and training. The greatest need for dementia-specific education is seen for general practitioners and nurses. An Internet-based education and skill-building program is considered to be equivalent to traditional face-to-face but offer advantages in terms of convenience of access. Assistive technology is available in countries of the Danube Region but is significantly underused. Conclusion: Dementia care in the Danube Region can be improved by an educational and skill-building program for health care professionals who work in the frontline of dementia care. Such a program should also attempt to enhance interdisciplinary and intersectorial collaboration, to intensify the interaction between primary care and specialists, and to promote the implementation of assistive technology.

8 October 2024 in Neurology
Verified
Journal Article
Open access
BBBarbara Borroni
Barbara Borroni
BTBarbara Tarantino
Barbara Tarantino
CGCaroline Graff
Caroline Graff
JKJohanna Krüger
Johanna Krüger
ALAlbert C. Ludolph
Albert C. Ludolph
FFFor Frontiers
For Frontiers
Data on care home admission and survival rates of patients with syndromes associated with frontotemporal lobar degeneration (FTLD) are limited. However, their estimation is essential to plan trials and assess the efficacy of intervention. Population-based registers provide unique samples for this estimate. The aim of this study was to assess care home admission rate, survival rate, and their predictors in incident patients with FTLD-associated syndromes from the European FRONTIERS register-based study. We conducted a prospective longitudinal multinational observational registry study, considering incident patients with FTLD-associated syndromes diagnosed between June 1, 2018, and May 31, 2019, and followed for up to 5 years till May 31, 2023. We enrolled patients fulfilling diagnosis of the behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), progressive supranuclear palsy (PSP) or corticobasal syndrome (CBS), and FTD with motor neuron disease (FTD-MND). Kaplan-Meier analysis and Cox multivariable regression models were used to assess care home admission and survival rates. The survival probability score (SPS) was computed based on independent predictors of survivorship. A total of 266 incident patients with FTLD were included (mean age ± SD = 66.7 ± 9.0; female = 41.4%). The median care home admission rate was 97 months (95% CIs 86–98) from disease onset and 57 months (95% CIs 56–58) from diagnosis. The median survival was 90 months (95% CIs 77–97) from disease onset and 49 months (95% CIs 44–58) from diagnosis. Survival from diagnosis was shorter in FTD-MND (hazard ratio [HR] 4.59, 95% CIs 2.49–8.76, p < 0.001) and PSP/CBS (HR 1.56, 95% CIs 1.01–2.42, p = 0.044) compared with bvFTD; no differences between PPA and bvFTD were found. The SPS proved high accuracy in predicting 1-year survival probability (area under the receiver operating characteristic curve = 0.789, 95% CIs 0.69–0.87), when defined by age, European area of residency, extrapyramidal symptoms, and MND at diagnosis. In FTLD-associated syndromes, survival rates differ according to clinical features and geography. The SPS was able to predict prognosis at individual patient level with an accuracy of ∼80% and may help to improve patient stratification in clinical trials. Future confirmatory studies considering different populations are needed.

7 June 2024 in neurogenetics
Verified
Journal Article
Closed access
PDF file
ESElka Stefanova
Elka Stefanova
AMAna Marjanovic
Ana Marjanovic
VDValerija Dobričić
Valerija Dobričić
GMGorana Mandić-Stojmenović
Gorana Mandić-Stojmenović
TSTanja Stojković
Tanja Stojković
VKVladimir S. Kostić
Vladimir S. Kostić